- About Us
- Business Development
Focusing solely on Animal Health to help customers meet real-world challenges
ZoetisTM, formerly the animal health business unit of Pfizer, today announced its vision for business in Europe, Africa and the Middle East (EuAfME). Building on 60 years of experience in the animal health sector, the company aims to have its products, services and people as the most valued by animal health customers around the region, and the world.
“We are united around this shared vision, and we strive every day to help customers meet their real-world challenges through quality medicines and vaccines, complemented by diagnostic products, genetic tests and a range of services,” said Alejandro Bernal, Zoetis Executive Vice President and Area President for the EuAfME region. “As the largest standalone company in the industry, we are dedicated solely to animal health and focusing on our core business so our customers can grow theirs.”
Such strong and sustainable business growth will be achieved through six key strategies, Mr Bernal said:
Working closer with customers and academics to address Animal Health needs
Zoetis combines local presence with strong customer relationships across the EuAfME region, where Zoetis has 2,600 colleagues, offices in 17 countries, (speaking 20 different languages), conducting business in more than 60 countries, Bernal told the meeting in Paris. That presence is backed by strong manufacturing and Research and Development capabilities; Zoetis has four manufacturing sites in Europe: Catania (Italy), Louvain-la-Neuve (Belgium), Medolla (Italy), Olot (Spain) and three Research and Development sites: Louvain-la-Neuve, Olot and Zaventem (Belgium).
“Our local presence, backed by our global reach and resources, allows us to work with customers to address their specific needs.”
In addition to working closely with customers, Zoetis strives to collaborate with universities and other research organisations, to help advance the animal health sector and those who raise and care for animals. One example of this is the partnership with the University of Stirling, one of the leading research organisations, based in Scotland.
“Academia is increasingly realising the benefits of working with industry on research projects, and is concentrating on those with more direct impact rather than on pure research,” said Professor Randolph Richards, from Stirling. “In our own case, Zoetis has been able to provide resources which were otherwise unavailable to us, with funding opportunity being provided through the UK Technology Strategy Board.”
Diversity as a strength
Mr Bernal said such research partnerships allow Zoetis to meet industry challenges head-on.
“We are a region with a broad diversity of markets, with a strong demand for protein (and production), and considerable growth in developing countries. But we have a broad portfolio of products and services, which together with the value created by our field force, makes Zoetis in EuAfME uniquely positioned to create strong relationships with customers.”
“Our diversity is the strength on which we deliver our promise to customers: for animals, for health, for you.”
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. The company generated annual revenue of $4.2 billion in fiscal 2011. Zoetis has more than 9,500 employees and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries.
DISCLOSURE NOTICE: This news release contains forward-looking statements, which reflect Zoetis’ current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of these risks, uncertainties and other factors can be found in Zoetis’ Registration Statement on Form S-1 (File No. 333-183254), as amended, filed with the Securities and Exchange Commission. This filing and subsequent filings are available online at www.sec.gov or on request from Zoetis.
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.